Rhiannon Jenkinson, Director of Science at Charles River, discusses the impact of the Tumor Microenvironment on immune-oncology drug development, and how the immune system can be harnessed to fight cancer. Related Resources Cell-Based Assays for the Tumor Microenvironment In Vitro Immuno-Oncology Assays Immuno-oncology Pharmacodynamic Models Oncology Pharmacology Models
Poster Adenovirus-Mediated CRISPR/Cas9 Gene Editing in Patient Primary Fibroblasts to Validate Potential Drug Targets in Lung Fibrosis Learn More
Poster SPARCLTM: use of a novel technology in validation of large animal inflammatory/injury biomarker assays in serum Learn More
